Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.46 |
| ▸ | MET | P08581 | 6/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084560 | 0.79 | RAB9A (0.47) | HTR6HTR7HTR2AHRH3TSHR | |
| SCHEMBL4075300 | 0.77 | HTR7 (0.45) | HTR6HTR7SIGMAR1TSHR | |
| SCHEMBL5753820 | 0.77 | HTR6 (0.55) | HTR6HTR7HTR2AHRH1HRH3 | |
| SCHEMBL4082363 | 0.76 | TSHR (0.44) | HTR6HTR2CHTR7HTR2BHTR2A | |
| SCHEMBL5756326 | 0.75 | HTR6 (0.46) | HTR6HTR7HRH3TSHR | |
| SCHEMBL4082426 | 0.74 | HTR6 (0.46) | HTR6HTR7HTR2AHRH3TSHR | |
| SCHEMBL4081092 | 0.74 | HTR6 (0.55) | HTR6METHTR2CHTR7CYP3A4 | |
| SCHEMBL4076472 | 0.72 | ALDH1A1 (0.47) | HTR6HRH3TSHR | |
| SCHEMBL5738773 | 0.72 | HTR6 (0.74) | HTR6METHTR2CHTR7CYP3A4 | |
| SCHEMBL4082858 | 0.71 | HTR6 (0.45) | HTR6HTR2CHTR7HTR2BHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239863-A1 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-09-24 | — | — | US | claimed |
| US-7271180-B2 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-09-18 | — | — | US | claimed |
| US-20050009819-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-13 | — | — | US | claimed |
| US-20090239863-A1 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-09-24 | — | — | US | disclosed |
| US-7541358-B2 | 1-Substituted indoles, benzimidazoles additionally substituted with an amino ligand, e.g., 1-[(5-chlorothien-2-yl)sulfonyl]-5-[2-(piperidin-1-yl)ethoxy]-1H-indole; treating schizophrenia, depression, attention deficit disorder, Alzheimer's disease and Parkinson's disease | WYETH (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080027055-A1 | 1-Aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-7271180-B2 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-09-18 | — | — | US | disclosed |
| US-20050009819-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239863-A1 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR1B, HTR1A | HTR6 1/4885MET 1205/4885HTR2C 7/4885 |
| US-20080027055-A1 | 1-Aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands | HTR6, HTR1B, HTR3B | HTR6 1/4885MET 1124/4885HTR2C 7/4885 |
| US-20050009819-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | HTR6 1/4885MET 1205/4885HTR2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.